With High Profile At FDA, Gottlieb Headed Ambitious Consumer Health Initiatives
Scott Gottlieb claimed higher profile than most previous FDA commissioners with frequent Twitter posts and by including his remarks in many agency communications to industries and consumers. In his nearly two years in post, he also had more central role in FDA initiatives in areas such as keeping unsafe products labeled as supplements off the market and explaining why hemp and CBD are available and supplements even though FDA considers the products noncompliant as dietary ingredients.
You may also be interested in...
Gottlieb Leaves FDA Feeling Good About Generic Approvals, But Concerned About Innovative Competition
FDA should formalize its internal policy on CBD enforcement or create a pathway to make it compliant for use in supplements, says NPA President Daniel Fabricant. NPA and PCPC submitted comments on FDA request for input on agency's action at ongoing United Nations meeting on drug policy.